Cooperative Agreement U34CA308743
Award Date 7/16/26
Completion Date 6/30/29
Dollars Obligated $427K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $197,518 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 8, 2025, through August 31, 2030. This award supports the development of a Rare Tumor Clinical Research Specialist position focused on addressing critical barriers in clinical research for rare cancers, which collectively account for 25% of cancer deaths despite...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded $276,545 to The Children's Hospital of Philadelphia Research Institute on June 8, 2026, for the development of genomic risk prediction models for T-cell malignancies. The project, which runs through May 31, 2031, addresses a critical gap in clinical care by developing and validating risk stratification tools for T-cell acute lymphoblastic leukemia (T-ALL) and...
- Federal Grant Award Summary The National Cancer Institute awarded The Children's Hospital of Philadelphia a $749,133 Project Grant (CFDA 93.393, Cancer Cause and Prevention Research) effective June 1, 2026, through May 31, 2031, to develop and evaluate DECIDES 2.0, an evidence-based decision support intervention designed to improve shared treatment-related decision-making for adolescents and young adults (AYA, ages 15-24) newly diagnosed with cancer. The primary deliverable is a randomized...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a $360,643 Cooperative Agreement to the University of Pittsburgh (award date: September 1, 2025; completion date: August 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to conduct preanalytical validation of circulating tumor DNA (ctDNA) from surgical drain fluid (SDF) as a biomarker for postoperative minimal residual disease (MRD) in head and neck squamous cell carcinoma (HNSCC). The project...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded St. Jude Children's Research Hospital Inc. a Cooperative Agreement totaling $1,059,908 under the Cancer Cause and Prevention Research program (CFDA 93.393), effective August 1, 2025 through July 31, 2030. This award supports the St. Jude Lifetime Cohort (SJLIFE) Study, which conducts longitudinal clinical assessment and health outcome monitoring of childhood cancer survivors across the lifespan. The study addresses...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded University of Wisconsin–Madison a $783,189 Cooperative Agreement on August 6, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop the Pediatric Brain Tumor Image Informatics (PBTI2) toolkit. This three-year project (completion date July 31, 2028) addresses the clinical challenge of optimizing treatment decisions for approximately 4,000 annual pediatric brain tumor cases by creating...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded The Ohio State University $327,020 on July 17, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct clinical validation of FGFR-DX, a cell-free DNA (cfDNA) assay designed to detect fibroblast growth factor receptor (FGFR) alterations in patients with advanced pancreatic cancer. The primary deliverable is a comprehensive, clinically validated diagnostic test that targets intronic...
- Federal Cooperative Agreement Summary The University of Michigan received a $210,600 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective September 1, 2025, through August 31, 2027. This award supports the analytical and clinical validation of an H3K27M circulating tumor DNA (ctDNA) assay designed to improve disease monitoring and early detection of progression in diffuse midline glioma (DMG) patients. The...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a $690,637 Cooperative Agreement to the Beckman Research Institute of the City of Hope, effective September 1, 2025 through August 31, 2030, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). This award supports the development and validation of a blood-based biomarker test for early detection of pancreatic ductal adenocarcinoma (PDAC) utilizing 5-methylcytosine (5MC) and 5-hydroxymethylcytosine...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded The Institute for Cancer Research a Cooperative Agreement totaling $263,670 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support clinical translation of a urine-based biomarker for detecting residual disease in radical cystectomy candidates. The award, effective May 1, 2026, through April 30, 2028, funds development and validation of the Noninvasive Test for Assessment of Cancerous...